Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

Herwig Ulf Meier-Kriesche, Bettina J. Steffen, Alan M. Hochberg, Robert D. Gordon, Michael N. Liebman, Jonathan A. Morris, Bruce Kaplan

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

To evaluate the association of long-term continuous (minimum 1 year) mycophenolate mofetil (MMF) vs. azathioprine (AZA) therapy with the incidence of late acute rejection, we analyzed 47 693 primary renal allograft recipients reported to the United States Renal Data System between 1988 and 1998. The primary study endpoint was acute rejection beyond 1 year after transplantation. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. All multivariate analyses were corrected for potential confounding covariates. Mycophenolate mofetil was associated with a 65% decreased risk of developing late acute rejection as compared to AZA (RR = 0.35, Cl 0.27-0.45, p <0.001). The incidence of acute rejection episodes at 2 and 3 years post-transplantation was significantly lower in the MMF group (0.9% at 2 years, 1.1% at 3 years) than the AZA group (6.1 % at 2 years, 9.3% at 3 years). In the primary vs. repeat late rejection analysis, MMF patients exhibited a decreased late acute rejection risk of 72% (RR=0.28, p <0.001) and 60%, respectively (RR=0.40, p <0.001). In African Americans, the late acute rejection risk was 70% lower in MMF patients than AZA patients (RR = 0.30, p <0.001). Further study is indicated to determine the optimal duration of MMF therapy after renal allograft transplantation.

Original languageEnglish (US)
Pages (from-to)68-73
Number of pages6
JournalAmerican Journal of Transplantation
Volume3
Issue number1
DOIs
StatePublished - Jan 2003
Externally publishedYes

Fingerprint

Mycophenolic Acid
Azathioprine
Incidence
Allografts
Transplantation
Kidney
Kaplan-Meier Estimate
Proportional Hazards Models
Information Systems
African Americans
Kidney Transplantation
Multivariate Analysis
Therapeutics

Keywords

  • Acute rejection
  • Azathioprine
  • Immunosuppression
  • Kidney transplantation
  • Mycophenolate mofetil

ASJC Scopus subject areas

  • Immunology

Cite this

Meier-Kriesche, H. U., Steffen, B. J., Hochberg, A. M., Gordon, R. D., Liebman, M. N., Morris, J. A., & Kaplan, B. (2003). Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. American Journal of Transplantation, 3(1), 68-73. https://doi.org/10.1034/j.1600-6143.2003.30112.x

Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. / Meier-Kriesche, Herwig Ulf; Steffen, Bettina J.; Hochberg, Alan M.; Gordon, Robert D.; Liebman, Michael N.; Morris, Jonathan A.; Kaplan, Bruce.

In: American Journal of Transplantation, Vol. 3, No. 1, 01.2003, p. 68-73.

Research output: Contribution to journalArticle

Meier-Kriesche, HU, Steffen, BJ, Hochberg, AM, Gordon, RD, Liebman, MN, Morris, JA & Kaplan, B 2003, 'Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection', American Journal of Transplantation, vol. 3, no. 1, pp. 68-73. https://doi.org/10.1034/j.1600-6143.2003.30112.x
Meier-Kriesche, Herwig Ulf ; Steffen, Bettina J. ; Hochberg, Alan M. ; Gordon, Robert D. ; Liebman, Michael N. ; Morris, Jonathan A. ; Kaplan, Bruce. / Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. In: American Journal of Transplantation. 2003 ; Vol. 3, No. 1. pp. 68-73.
@article{76500c591753466eaedcf2e83cdc9861,
title = "Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection",
abstract = "To evaluate the association of long-term continuous (minimum 1 year) mycophenolate mofetil (MMF) vs. azathioprine (AZA) therapy with the incidence of late acute rejection, we analyzed 47 693 primary renal allograft recipients reported to the United States Renal Data System between 1988 and 1998. The primary study endpoint was acute rejection beyond 1 year after transplantation. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. All multivariate analyses were corrected for potential confounding covariates. Mycophenolate mofetil was associated with a 65{\%} decreased risk of developing late acute rejection as compared to AZA (RR = 0.35, Cl 0.27-0.45, p <0.001). The incidence of acute rejection episodes at 2 and 3 years post-transplantation was significantly lower in the MMF group (0.9{\%} at 2 years, 1.1{\%} at 3 years) than the AZA group (6.1 {\%} at 2 years, 9.3{\%} at 3 years). In the primary vs. repeat late rejection analysis, MMF patients exhibited a decreased late acute rejection risk of 72{\%} (RR=0.28, p <0.001) and 60{\%}, respectively (RR=0.40, p <0.001). In African Americans, the late acute rejection risk was 70{\%} lower in MMF patients than AZA patients (RR = 0.30, p <0.001). Further study is indicated to determine the optimal duration of MMF therapy after renal allograft transplantation.",
keywords = "Acute rejection, Azathioprine, Immunosuppression, Kidney transplantation, Mycophenolate mofetil",
author = "Meier-Kriesche, {Herwig Ulf} and Steffen, {Bettina J.} and Hochberg, {Alan M.} and Gordon, {Robert D.} and Liebman, {Michael N.} and Morris, {Jonathan A.} and Bruce Kaplan",
year = "2003",
month = "1",
doi = "10.1034/j.1600-6143.2003.30112.x",
language = "English (US)",
volume = "3",
pages = "68--73",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

AU - Meier-Kriesche, Herwig Ulf

AU - Steffen, Bettina J.

AU - Hochberg, Alan M.

AU - Gordon, Robert D.

AU - Liebman, Michael N.

AU - Morris, Jonathan A.

AU - Kaplan, Bruce

PY - 2003/1

Y1 - 2003/1

N2 - To evaluate the association of long-term continuous (minimum 1 year) mycophenolate mofetil (MMF) vs. azathioprine (AZA) therapy with the incidence of late acute rejection, we analyzed 47 693 primary renal allograft recipients reported to the United States Renal Data System between 1988 and 1998. The primary study endpoint was acute rejection beyond 1 year after transplantation. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. All multivariate analyses were corrected for potential confounding covariates. Mycophenolate mofetil was associated with a 65% decreased risk of developing late acute rejection as compared to AZA (RR = 0.35, Cl 0.27-0.45, p <0.001). The incidence of acute rejection episodes at 2 and 3 years post-transplantation was significantly lower in the MMF group (0.9% at 2 years, 1.1% at 3 years) than the AZA group (6.1 % at 2 years, 9.3% at 3 years). In the primary vs. repeat late rejection analysis, MMF patients exhibited a decreased late acute rejection risk of 72% (RR=0.28, p <0.001) and 60%, respectively (RR=0.40, p <0.001). In African Americans, the late acute rejection risk was 70% lower in MMF patients than AZA patients (RR = 0.30, p <0.001). Further study is indicated to determine the optimal duration of MMF therapy after renal allograft transplantation.

AB - To evaluate the association of long-term continuous (minimum 1 year) mycophenolate mofetil (MMF) vs. azathioprine (AZA) therapy with the incidence of late acute rejection, we analyzed 47 693 primary renal allograft recipients reported to the United States Renal Data System between 1988 and 1998. The primary study endpoint was acute rejection beyond 1 year after transplantation. Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models were used to investigate the risk of reaching the study endpoints. All multivariate analyses were corrected for potential confounding covariates. Mycophenolate mofetil was associated with a 65% decreased risk of developing late acute rejection as compared to AZA (RR = 0.35, Cl 0.27-0.45, p <0.001). The incidence of acute rejection episodes at 2 and 3 years post-transplantation was significantly lower in the MMF group (0.9% at 2 years, 1.1% at 3 years) than the AZA group (6.1 % at 2 years, 9.3% at 3 years). In the primary vs. repeat late rejection analysis, MMF patients exhibited a decreased late acute rejection risk of 72% (RR=0.28, p <0.001) and 60%, respectively (RR=0.40, p <0.001). In African Americans, the late acute rejection risk was 70% lower in MMF patients than AZA patients (RR = 0.30, p <0.001). Further study is indicated to determine the optimal duration of MMF therapy after renal allograft transplantation.

KW - Acute rejection

KW - Azathioprine

KW - Immunosuppression

KW - Kidney transplantation

KW - Mycophenolate mofetil

UR - http://www.scopus.com/inward/record.url?scp=0346525123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346525123&partnerID=8YFLogxK

U2 - 10.1034/j.1600-6143.2003.30112.x

DO - 10.1034/j.1600-6143.2003.30112.x

M3 - Article

C2 - 12492713

AN - SCOPUS:0346525123

VL - 3

SP - 68

EP - 73

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 1

ER -